NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 100
- Market Cap
- $3.3B
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
SentiSense also tracks daily options readings for NewAmsterdam Pharma Company N.V. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
NewAmsterdam Pharma Company N.V. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.